What is HC Wainwright's Forecast for ZVRA FY2027 Earnings?

Key Points

• HC Wainwright has revised its earnings per share estimate for Zevra Therapeutics for FY2027 from $1.92 to $1.78, while maintaining a "Buy" rating and a price target of $26.00.
• During its latest earnings report, Zevra Therapeutics missed analysts' expectations with an EPS of ($0.06) compared to the estimated $1.43, despite revenues of $25.88 million exceeding expectations.
• Shares of Zevra Therapeutics have experienced a drop of 8.1%, with recent trades highlighting a price of $8.67 per share.

Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) - Analysts at HC Wainwright dropped their FY2027 EPS estimates for shares of Zevra Therapeutics in a research report issued on Wednesday, August 13th. HC Wainwright analyst B. Folkes now forecasts that the company will earn $1.78 per share for the year, down from their prior estimate of $1.92. HC Wainwright has a "Buy" rating and a $26.00 price target on the stock. The consensus estimate for Zevra Therapeutics' current full-year earnings is ($1.95) per share. HC Wainwright also issued estimates for Zevra Therapeutics' FY2029 earnings at $3.45 EPS.

ZVRA has been the topic of a number of other research reports. Citigroup reissued an "outperform" rating on shares of Zevra Therapeutics in a report on Wednesday, August 13th. Wall Street Zen lowered shares of Zevra Therapeutics from a "strong-buy" rating to a "buy" rating in a report on Sunday, July 20th. JMP Securities decreased their price target on shares of Zevra Therapeutics from $19.00 to $18.00 and set a "market outperform" rating on the stock in a report on Wednesday, August 13th. Finally, Cantor Fitzgerald increased their price target on shares of Zevra Therapeutics from $25.00 to $29.00 and gave the stock an "overweight" rating in a report on Thursday, July 10th. One research analyst has rated the stock with a Strong Buy rating and eight have issued a Buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Buy" and an average target price of $23.71.

Zevra Therapeutics Price Performance

Zevra Therapeutics stock traded down $0.1350 during midday trading on Thursday, reaching $9.0650. 883,440 shares of the stock were exchanged, compared to its average volume of 731,279. The company's fifty day moving average is $10.56 and its 200-day moving average is $8.77. The firm has a market cap of $508.82 million, a PE ratio of -43.19 and a beta of 1.87. Zevra Therapeutics has a 52 week low of $6.19 and a 52 week high of $13.16. The company has a debt-to-equity ratio of 0.52, a quick ratio of 7.81 and a current ratio of 7.85.

Institutional Investors Weigh In On Zevra Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. Price T Rowe Associates Inc. MD increased its stake in shares of Zevra Therapeutics by 51.2% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 20,565 shares of the company's stock worth $172,000 after acquiring an additional 6,966 shares in the last quarter. BNP Paribas Financial Markets bought a new position in shares of Zevra Therapeutics in the 4th quarter worth about $53,000. Millennium Management LLC increased its stake in shares of Zevra Therapeutics by 138.2% in the 4th quarter. Millennium Management LLC now owns 233,132 shares of the company's stock worth $1,944,000 after acquiring an additional 135,246 shares in the last quarter. Deutsche Bank AG increased its stake in shares of Zevra Therapeutics by 25.4% in the 4th quarter. Deutsche Bank AG now owns 50,906 shares of the company's stock worth $425,000 after acquiring an additional 10,306 shares in the last quarter. Finally, ProShare Advisors LLC bought a new position in shares of Zevra Therapeutics in the 4th quarter worth about $145,000. 35.03% of the stock is owned by hedge funds and other institutional investors.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.